Vericel announced that the FDA has approved a pediatric indication for NexoBrid for eschar removal in pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCEL:
- Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
- Vericel initiated with a Buy at Canaccord
- Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
- Vericel price target raised to $60 from $55 at H.C. Wainwright
- Vericel sees 2024 revenue $238M-$242M, consensus $240.28M